Teva Pharmaceutical Industries - Generic Company Intelligence Report

SUMMARY

Teva Pharmaceutical Industries has its headquarters in Israel; it was incorporated in Israel in 1944, and is the successor to a number of Israeli corporations, the oldest of which was established in Jerusalem in 1901. This report provides an insight into the company, reviewing its current business structure and activities.

In 1951, Teva, as one of the first industrial companies in Israel, raised funds through an initial public offering on the Tel Aviv stock exchange. In 1964, Assia and Zori, two Israeli drug firms, merged and later acquired a controlling interest in Teva. The three firms formally merged in 1976, becoming Teva Pharmaceutical Industries.

In 1982, Teva first entered the US market, after gaining FDA approval for its manufacturing site. At the same time, Teva commenced trading its American Depository Receipts on the NASDAQ market. In 1985, a joint company was set up between Teva and the US' WR Grace. Lemmon, a small Pennsylvania-based generic manufacturer, was acquired in 1986. During the 1990s, Teva bought out WR Grace's interest in the joint venture. The 1990s also saw Teva move into the European market, and the launch of Teva's proprietary multiple sclerosis product, Copaxone.

In 2000, Teva acquired Canada's Novopharm, which led to Teva becoming the largest generic pharmaceutical company in North America. The company continued to expand its global presence, acquiring Teva Classics (previously Bayer) in France, and the Honeywell Fine Pharmaceutical Chemical plants in northern Italy (since renamed Teva PFC) in 2002. In 2004, Teva acquired Sicor, another US generic firm with a generic injectable business and a biogenerics capability.

In January 2006, Teva completed its acquisition of IVAX, further strengthening Teva's global presence, and ensuring the company's position as the largest generic pharmaceutical firm in the world. As a result, Teva now operates directly in over 50 countries, and employs in the region of 25,000 people.

This report provides information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances and litigation. The company's most recent quarterly and annual financial results are illustrated with comparative figures, charts and a detailed review of the data which allows you to track the company's progress.

TABLE OF CONTENTS

• EXECUTIVE SUMMARY
• INTRODUCTION
• PRODUCTS
  • Teva ANDA Approvals 2002-06
  • Sicor ANDA Approvals, 2003-05
  • Pharmachemie ANDA Approvals, 2003-
  • Novopharm ANDA Approvals, 2003-05
  • IVAX ANDA Approvals, 2002-05
  • Goldline Laboratories / Zenith Goldline ANDA Approvals, 2002-05
• Recent product approvals - Tev 9
  • Topiramate (tentative)
  • Ondansetron (tentative)
  • Rabeprazole (tentative)
  • Adenosine (tentative)
  • Desmopressin
  • Divalproex sodium (tentative)
  • Zonisamide
  • Simvastatin (tentative)
  • Oxycodone
  • Cefprozil
  • Zaleplon (tentative)
  • Ribavirin
  • Azithromycin
  • Glipizide and metformin
  • Gatifloxacin tablets
  • Glimepiride
  • Ribavirin (tentative)
  • Leflunomide tablets
  • Granisetron injection (tentative)
  • Paroxetine tablets
  • Risedronate tablets (tentative)
  • Tramadol+acetaminophen (tentative)
  • Mirtazapine
  • Clarithromycin
  • Zolpidem tartrate tablets (tentative)
  • Fenofibrate
  • Clozapine
  • Metformin extended-release tablets
  • Octreotide acetate (tentative)
  • Olanzapine
  • Amlodipine besylate (tentative)
  • Glyburide and metformin
  • Methylprednisolone
  • Savient and Teva launch somatropin human growth hormone
  • Levofloxacin
• Recent product approvals - I
  • Clozapine
• FINANCIAL RESULTS
  • Latest Full Year Highlights
    • Full Year Results, 2001 - 2005
    • Segment Data
    • Segment Results, 2004 - 2005
    • Geographic Segment
    • Revenues by Geographic Region, 2004 - 2005
• MAJOR DEVELOPMENTS
  • Mergers, acquisitions and agreements
    • Teva announces purchase of IVAX Pharmaceuticals
    • Teva and Barr sign agreement covering fexofenadine
    • Teva and TransPharma sign transdermal drug delivery agreement
    • Dorom
    • Alpharma and Teva enter gabapentin agreement
    • Microbia.
    • Sicor
    • Impax
  • Litigation
    • Esomeprazole magnesium
    • Adderall
    • Azithromycin products
    • Fexofenadine
    • Venlafaxine
    • Modafinil.
    • Missouri AG alleges firms involved in AWP inflation scheme
    • Donezepril hydrochloride
    • Quinapril
    • Quetiapine fumarate
    • Pravastatin
    • Gatifloxacin tablets
    • Lovenox
    • Court grants Abbot's motion for injunction of Teva's clarithromycin
    • Astellas/ITEM/King file lawsuit against Teva for Adenoscan patent infringement
    • Florida Medicaid
    • Hydrocodone / Ibuprofen
    • Moexipril
• CONTACT DETAILS